|
|
|
|
|
|
|
|
|
|
open access - pdf
Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO,
AGO Austria and AGO Switzerland Regarding the Use of Hyperthermic
Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer
The AGO Kommission Ovar already published a statement in 2013, warning about the uncritical use of hyperthermic intraperitoneal chemotherapy (HIPEC) outside controlled studies. This statement has now been updated after the most recent literature was reviewed by AGO Kommission Ovar, the AGO Study Group, NOGGO, AGO Austria and AGO Switzerland. The authors conclude that HIPEC remains experimental. Its use is not recommended and should be rejected outside of prospective controlled trials.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.